WO2023047127A1 - Bont/a modifiée destinée à être utilisée dans le traitement d'un trouble affectant un muscle de la paupière d'un sujet - Google Patents
Bont/a modifiée destinée à être utilisée dans le traitement d'un trouble affectant un muscle de la paupière d'un sujet Download PDFInfo
- Publication number
- WO2023047127A1 WO2023047127A1 PCT/GB2022/052415 GB2022052415W WO2023047127A1 WO 2023047127 A1 WO2023047127 A1 WO 2023047127A1 GB 2022052415 W GB2022052415 W GB 2022052415W WO 2023047127 A1 WO2023047127 A1 WO 2023047127A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- unit dose
- muscle
- asn
- modified bont
- bont
- Prior art date
Links
- 210000003205 muscle Anatomy 0.000 title claims abstract description 1364
- 238000011282 treatment Methods 0.000 title claims abstract description 150
- 210000000744 eyelid Anatomy 0.000 title description 53
- 101100272852 Clostridium botulinum (strain Langeland / NCTC 10281 / Type F) F gene Proteins 0.000 title description 2
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 claims abstract description 1347
- 238000000034 method Methods 0.000 claims abstract description 176
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims abstract description 88
- 101710117524 Botulinum neurotoxin type B Proteins 0.000 claims abstract description 82
- 108020003175 receptors Proteins 0.000 claims abstract description 82
- 102000005962 receptors Human genes 0.000 claims abstract description 82
- 230000005945 translocation Effects 0.000 claims abstract description 82
- 238000010255 intramuscular injection Methods 0.000 claims abstract description 79
- 239000007927 intramuscular injection Substances 0.000 claims abstract description 79
- 206010005159 blepharospasm Diseases 0.000 claims abstract description 58
- 230000000744 blepharospasm Effects 0.000 claims abstract description 58
- 125000000539 amino acid group Chemical group 0.000 claims description 597
- 206010063006 Facial spasm Diseases 0.000 claims description 314
- 208000004095 Hemifacial Spasm Diseases 0.000 claims description 306
- 229940037201 oris Drugs 0.000 claims description 217
- 238000006467 substitution reaction Methods 0.000 claims description 201
- 230000002378 acidificating effect Effects 0.000 claims description 198
- 230000004048 modification Effects 0.000 claims description 138
- 238000012986 modification Methods 0.000 claims description 138
- 241000225674 Procerus Species 0.000 claims description 69
- 238000012217 deletion Methods 0.000 claims description 66
- 230000037430 deletion Effects 0.000 claims description 66
- 238000003780 insertion Methods 0.000 claims description 66
- 230000037431 insertion Effects 0.000 claims description 66
- 241000158526 Nasalis Species 0.000 claims description 64
- 241000223503 Platysma Species 0.000 claims description 64
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 61
- 210000001352 masseter muscle Anatomy 0.000 claims description 61
- 238000002347 injection Methods 0.000 claims description 18
- 239000007924 injection Substances 0.000 claims description 18
- 229920001184 polypeptide Polymers 0.000 claims description 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 3
- 150000007523 nucleic acids Chemical group 0.000 claims 3
- 108091005804 Peptidases Proteins 0.000 claims 2
- 239000004365 Protease Substances 0.000 claims 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 2
- 230000004913 activation Effects 0.000 claims 2
- 239000004475 Arginine Chemical group 0.000 claims 1
- 208000031648 Body Weight Changes Diseases 0.000 claims 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical group NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Chemical group OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 1
- 230000004579 body weight change Effects 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 239000003053 toxin Substances 0.000 claims 1
- 231100000765 toxin Toxicity 0.000 claims 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1020
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1020
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 180
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 60
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 55
- 208000035475 disorder Diseases 0.000 description 55
- 231100000111 LD50 Toxicity 0.000 description 47
- 241000699670 Mus sp. Species 0.000 description 47
- 231100000636 lethal dose Toxicity 0.000 description 47
- 239000003814 drug Substances 0.000 description 35
- 238000004519 manufacturing process Methods 0.000 description 32
- 208000024891 symptom Diseases 0.000 description 12
- 238000011269 treatment regimen Methods 0.000 description 7
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 6
- 229940098753 dysport Drugs 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 5
- 231100000419 toxicity Toxicity 0.000 description 5
- 230000001988 toxicity Effects 0.000 description 5
- 206010028347 Muscle twitching Diseases 0.000 description 4
- 210000005036 nerve Anatomy 0.000 description 4
- 230000009471 action Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 108030001720 Bontoxilysin Proteins 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 210000001097 facial muscle Anatomy 0.000 description 2
- 210000000256 facial nerve Anatomy 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000000216 zygoma Anatomy 0.000 description 2
- 208000014644 Brain disease Diseases 0.000 description 1
- 206010019196 Head injury Diseases 0.000 description 1
- 208000016285 Movement disease Diseases 0.000 description 1
- 208000029578 Muscle disease Diseases 0.000 description 1
- 208000021642 Muscular disease Diseases 0.000 description 1
- WXOMTJVVIMOXJL-BOBFKVMVSA-A O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)O.O[Al](O)OS(=O)(=O)OC[C@H]1O[C@@H](O[C@]2(COS(=O)(=O)O[Al](O)O)O[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]2OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@@H]1OS(=O)(=O)O[Al](O)O WXOMTJVVIMOXJL-BOBFKVMVSA-A 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 125000000129 anionic group Chemical group 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 210000004227 basal ganglia Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 230000004321 blink reflex Effects 0.000 description 1
- 230000004397 blinking Effects 0.000 description 1
- 229940089093 botox Drugs 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000006931 brain damage Effects 0.000 description 1
- 231100000874 brain damage Toxicity 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000002566 clonic effect Effects 0.000 description 1
- 230000009514 concussion Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 230000009881 electrostatic interaction Effects 0.000 description 1
- 238000009164 estrogen replacement therapy Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- -1 for example Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000012977 invasive surgical procedure Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000001640 nerve ending Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000003518 presynaptic effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000306 recurrent effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000016978 synaptic transmission, cholinergic Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003204 tranquilizing agent Substances 0.000 description 1
- 229940018272 xeomin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
Definitions
- the present invention relates to treatment of a disorder affecting an eyelid muscle of a subject.
- blepharospasm and facial spasm are particularly unpleasant.
- Blepharospasm is characterized primarily by abnormal contractions of the orbicularis oculi muscles. More specifically, blepharospasm can manifest as an uncontrollable excessive blinking and spasming of one or both eyes that is further characterized by uncontrollable eyelid closure of durations longer than the typical blink reflex. Blepharospasm symptoms can be recurrent and may last for a few hours or days at a time and, in some cases, the symptoms (e.g. twitching) may be chronic and persistent, causing life-long challenges for subjects suffering from the condition. Other symptoms may include twitching that can radiate into the nose, face and neck, dryness of the eyes, and sensitivity to the sun and bright lights.
- blepharospasm can be induced by certain drugs such as, for example, drugs to treat Parkinson's disease, estrogen-replacement therapy, or acute withdrawal from benzodiazepines.
- Blepharospasm may also be associated with brain disorders (e.g. including neurodegenerative conditions, abnormal functioning of the brain's basal ganglia, and multiple sclerosis), brain damage, or head injuries (e.g. concussion).
- Hemifacial spasm is a movement disorder that is characterized by involuntarily tonic - clonic contractions of the mimetic muscles on one side of the face. While bilateral cases are sometimes seen, they are extremely rare. Affected muscles are those innervated by the facial nerve (cranial nerve VII). Initially, symptoms of the disorder are typically located to the orbicularis oculi muscle (e.g. typical hemifacial spasm) and may spread to include other muscles of facial expression. Hemifacial spasm (HFS) takes two forms: typical HFS and atypical HFS. In the typical form, the twitching/ spasm typically begins in the lower eyelid in orbicularis oculi muscle.
- HFS Hemifacial spasm
- twitching/ spasm typically begins in orbicularis oris muscle around the lips, and buccinator muscle in the cheekbone area in the lower face, then progresses up to the orbicularis oculi muscle in the eyelid over time.
- the most common form is the typical form, and atypical form is only seen in about 2-3% of patients with hemifacial spasm.
- Drug therapy for disorders affecting an eyelid muscle of a subject has proven generally unpredictable and short-termed.
- Anticholinergics, tranquillizing drugs and botulinum neurotoxins e.g. Dysport®, Botox® or Xeomin®
- these treatment options are not optimal and are associated with serious side effects, including toxicity and unwanted paralysis of facial muscles.
- invasive surgical procedure may be envisaged for patients who do not respond well to medication or botulinum neurotoxin injection.
- new and effective therapies for the treatment of blepharospasm are constantly being tested or sought after.
- BoNT/A botulinum neurotoxin A selectively inhibits the release of acetylcholine from the presynaptic nerve terminals and thus blocks cholinergic transmission at the neuromuscular junction inducing a reduction in the muscle contraction and muscle tone, causing the injected muscles to relax.
- the duration of action of the currently available BoNT/A products is about 12 to 14 weeks, which is when the new nerve endings sprout allowing the nerve function to return to normal, and the original symptoms reappear. Consequently, for the effect to be maintained, injections need to be repeated periodically.
- the frequency of BoNT/A injections is an important consideration for the treatment of disorders affecting an eyelid muscle of a subject (e.g.
- Dysport® is approved for the treatment of blepharospasm and hemifacial spasm with a maximum total dose per treatment session of 120 Units per eye.
- a clinician is required to administer Dysport® to an eyelid muscle of the subject up to the upper threshold of 120 Units total per eye per treatment session (i.e. 240 Units when treating both eyes).
- the clinician is forced to make difficult choices during treatment of a patient.
- a clinician must find a balance between the relatively low total amount of BoNT/A that can be administered (necessitated by the highly toxic nature of BoNT/A) and the effective amount at a plurality of different muscles and/or sites thereof. Hence, certain muscles may be neglected while others receive a suboptimal amount of BoNT/A, resulting in suboptimal therapy.
- the present invention overcomes one or more of the above-mentioned problems.
- a modified BoNT/A finds particular utility in treating a disorder affecting an eyelid muscle of a subject (e.g. blepharospasm and/or hemifacial spasm).
- the modified BoNT/A may comprise a BoNT/A light-chain and translocation domain and a BoNT/B receptor binding domain (He domain), which results in a modified BoNT/A that exhibits increased retention at (reduced diffusion away from) a site of administration and/or increased duration of action (e.g. 6-9 months).
- the modified BoNT/A may comprise one or more modifications of surface exposed amino acid residues resulting in an increased net positive charge.
- the increased charge promotes electrostatic interactions between the polypeptide and anionic extracellular components, thereby promoting binding between the polypeptide and cell surface. In turn this also increases retention at (reduces diffusion away from) a site of administration and/or results in an increased duration of action (e.g. 6-9 months).
- modified BoNT/A has a safety profile that is improved when compared to unmodified BoNT/A (e.g. Dysport®).
- This improved safety profile may be expressed by the high Safety Ratio described herein for the modified BoNT/A.
- a higher total amount of modified BoNT/A may be administered to a subject while achieving a similar safety profile to unmodified BoNT/A (e.g. Dysport®) while at such high doses.
- more modified BoNT/A may be injected and/or may be injected at a greater number of muscles and/or sites thereof in the treatment of a disorder affecting an eyelid muscle of a subject (e.g.
- the treatment may be improved in that it provides for longer-lasting treatment (resulting in less frequent administration) and/or is capable of being tailored for the subject and/or results in an improved quality of life of a subject when compared to treatment with unmodified BoNT/A (e.g. Dysport®).
- BoNT/A e.g. Dysport®
- the present invention provides a convenient, safe, and effective single unit dose as well as a total (maximum) dosage that can be safely administered in a single treatment.
- the present invention also provides a corresponding guide to the number of times at which said unit dose can be administered to a muscle (e.g. including the number of injection sites per muscle) without resultant patient toxicity.
- Treatment of a disorder affecting an eyelid muscle of a subject e.g. blepharospasm and/or hemifacial spasm
- treatment according to the invention is much more satisfactory to the patient, as it is better tailored to the patient’s needs, when compared to conventional treatments.
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a
- the eye proximal to the injection site may be referred to as an eye affected by the disorder.
- the term “the lateral upper orbicularis oculi muscle” may refer to “the lateral pretarsal orbicularis oculi muscle of the upper eyelid”.
- the term “the medial upper orbicularis oculi muscle” may refer to “the medial pretarsal orbicularis oculi muscle of the upper eyelid”.
- the term “the lateral lower orbicularis oculi muscle” may refer to “the lateral pretarsal orbicularis oculi muscle of the lower eyelid”.
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain
- treating a disorder affecting an eyelid muscle of a subject may mean that one or more symptoms of said disorder of the subject are reduced.
- treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A may mean that one or more symptoms of said disorder of the subject are reduced for a longer time period following administration of a modified BoNT/A of the invention, when compared to administration of an unmodified BoNT/A. Said reduction may be determined by comparison to an equivalent control subject exhibiting equivalent symptoms that has been treated with an unmodified BoNT/A. At a time period where the severity of one or more symptoms of the control subject are substantially the same (e.g.
- a subject treated with a modified BoNT/A according to the invention may exhibit an improvement in the equivalent one or more symptoms of at least 5%, 10%, 25%, or 50% when compared to the severity of the one or more symptoms before treatment with the modified BoNT/A.
- the unmodified BoNT/A is preferably SEQ ID NO: 2 present in a di-chain form.
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of a medicament for treating a disorder affecting an eyelid muscle of a subject, comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and
- the invention provides use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- SEQ ID NO: 2 comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding
- One aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and
- the invention provides a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and where
- the invention provides a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- SEQ ID NO: 2 comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- HN BoNT/A light-
- Another aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides a method of treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hem
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- BoNT/A botulinum neurotoxin A
- a method of treating atypical hemifacial spasm wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a botulinum neurotoxin A (BoNT/A) lightchain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- BoNT/A botulinum neurotoxin A
- the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a botulinum neurotoxin A (BoNT/A) lightchain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides a method of treating atypical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a botulinum neurotoxin A (BoNT/A) lightchain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides a method of treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a botulinum neurotoxin A (BoNT/A) lightchain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating atypical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a botulinum neurotoxin A (BoNT/A) lightchain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- BoNT/A botulinum neurotoxin A
- the unit dose of the modified BoNT/A is at least 240 pg (preferably 240 pg to 8,000 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 24,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a botulinum neurotoxin A (BoNT/A) lightchain and translocation domain (HN), and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- HN botulinum neurotoxin A
- He domain BoNT/B receptor binding domain
- hemifacial spasm typically hemifacial spasm
- hemifacial spasm typically used interchangeably with the term “hemifacial spasm” throughout this disclosure.
- the unit dose may be at least 240.4 pg, 500 pg, 1 ,000 pg, 2,000 pg, 3,000 pg or 4,000 pg, preferably at least 1 ,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the upper limit of a unit dose of the invention may be determined based on the total dose administered during the treatment and the number of muscles and/or sites thereof to which the modified BoNT/A is administered. For example, where the total dose administered during the treatment is up to 24,000 pg of modified BoNT/A and administration is to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject, the medial upper orbicularis oculi muscle proximal to the first eye, and the lateral lower orbicularis oculi muscle proximal to the first eye only, then the upper limit of the unit dose may be 8,000 pg.
- the upper limit may be 4,000 pg (e.g. upper limit of 4,000 pg per eye).
- the unit dose may be 240 pg to 10,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 240 pg to 9,500 pg of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 240 pg to 9,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 240 pg to 8,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- An upper limit of the unit dose range may be 7,500, 7,000, 6,500, 6,000, 5,500, 5,000, 4,800, 4,500, 4,000, 3,500, 3,000, 2,500, 2,400, 2,000, 1,500, or 1,250 pg of modified BoNT/A.
- a lower limit of the unit dose range may be 300, 400, 500, 600, 700, 800, 900, 1 ,000, 1 ,500, 2,000, 2,500, 3,000, 3,500, 4,000, 4,500, or 5,000 pg of modified BoNT/A, preferably the lower limit is 1 ,000 pg.
- the unit dose may be 1 ,000 pg to 4,800 pg, 1 ,000 pg to 4,000 pg, 1 ,000 pg to 2,400 pg, or 1 ,000 pg to 2,000 pg.
- the unit dose may be 240.4 pg, 500 pg, 1 ,000 pg, 2,000 pg, 3,000 pg, 4,000 pg, 5,000 pg, 6,000 pg, 7,000 pg or 8,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 240.4 pg, 500 pg, 1 ,000 pg, 2,000 pg, 3,000 pg or 4,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 1 ,000 pg, 2,000 pg, 3,000 pg or 4,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- a total dose administered when carrying out the treatment regimen of the present invention may be up to 24,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the total amount of modified BoNT/A administered at a given treatment session may be up to 24,000 pg.
- the total dose may be up to 20,000, 15,000, 10,000, 7,500, or 6,000 pg.
- the total dose may be at least 720, 800, 900, 1,000, 2,000, 3,000, 4,000, 5,000, 7,500, 10,000, 12,500, 15,000, or 20,000 pg.
- the total dose may be at least 3,000 pg of modified BoNT/A.
- the total dose may be 720 pg to 24,000 pg, preferably 3,000 pg to 24,000 pg.
- the total dose may be 720, 800, 900, 1 ,000, 2,000, 3,000, 4,000, 5,000, 7,500, 10,000, 12,500, 15,000, or 20,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the total dose may be 6,000 pg, 7,500 pg, 10,000 pg, 15,000 pg or 20,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 1,000 pg and the total dose may be 6,000 pg, 7,500 pg, 10,000 pg, 15,000 pg or 20,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 2,000 pg and the total dose may be 6,000 pg, 7,500 pg, 10,000 pg, 15,000 pg or 20,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 3,000 pg and the total dose may be 6,000 pg, 7,500 pg, 10,000 pg, 15,000 pg or 20,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 4,000 pg and the total dose may be 6,000 pg, 7,500 pg, 10,000 pg, 15,000 pg or 20,000 pg, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT
- U
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- U Units
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating a disorder affecting an eyelid muscle of a subject, comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT
- U
- the invention provides use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- SEQ ID NO: 2 comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the
- the invention provides a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment
- LD50
- the invention provides a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- SEQ ID NO: 2 comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (
- Another aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in
- U Units
- 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- U Units
- 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a method of treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen: (i) one unit dose of the modified Bo
- U Units
- 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or
- U Units
- 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hem
- U Units
- 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- U Units
- 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- BoNT/A botulinum neurotoxin A
- a method of treating atypical hemifacial spasm wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- BoNT/A botulinum neurotoxin A
- the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a method of treating atypical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a method of treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating atypical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- BoNT/A botulinum neurotoxin A
- the unit dose of the modified BoNT/A is at least 10 Units (U) of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 998 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be at least 21 U, 42 U, 83 U, 125 U, or 166 U, preferably at least 42 U, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 10 U to 332.7 U of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- An upper limit of the unit dose range may be 312, 291, 270, 250, 229, 208, 199.6, 187, 166.3, 146, 125, 104, 99.8, 89.17, 62, or 52 U of modified BoNT/A.
- a lower limit of the unit dose range may be 12, 17, 21 , 25, 29, 33, 37, 42, 62, 83, 104, 125, 146, 166, 187, or 208 U of modified BoNT/A, preferably the lower limit is 42 U.
- the unit dose may be 42 U to 199.6 U, 42 U to 166.3 U, 42 U to 99.8 U, or 42 U to 83.17 U.
- the unit dose may be 10 Units, 20.8 Units, 41.6 Units, 83.2 Units, 124.8 Units, 166.4 Units, 207.8 Units, 249.6 Units, 291.2 Units or 332.8 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 10 Units, 20.8 Units, 41.6 Units, 83.2 Units, 124.8 Units, or 166.4 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 41.6 Units, 83.2 Units, 124.8 Units, or 166.4 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- a total dose administered when carrying out the treatment regimen of the present invention may be up to 998 U of modified BoNT/A, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the total amount of modified BoNT/A administered at a given treatment session may be up to 998 II.
- the total dose may be up to 832, 624, 416, 312, or 250 II.
- the total dose may be at least 30, 33, 37, 42, 83, 125, 166, 208, 312, 416, 520, 624, or 832 U.
- the total dose may be at least 125 II of modified BoNT/A.
- the total dose may be 30 U to 998 U, preferably 125 U to 998 U.
- the total dose may be 29.9 Units, 33.3 Units, 37.4 Units, 41.6 Units, 83.2 Units, 124.8 Units, 166.4 Units, 208 Units, 312 Units, 416 Units, 520 Units, 624 Units, or 831.9 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the total dose may be 249.6 Units, 312 Units, 416 Units, 624 Units, or 831.9 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 41.6 Units and the total dose may be 249.6 Units, 312 Units, 416 Units, 624 Units, or 831.9 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 83.2 Units and the total dose may be 249.6 Units, 312 Units, 416 Units, 624 Units, or 831.9 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 124.8 Units and the total dose may be 249.6 Units, 312 Units, 416 Units, 624 Units, or 831.9 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the unit dose may be 166.4 Units and the total dose may be 249.6 Units, 312 Units, 416 Units, 624 Units, or 831.9 Units, wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the modified BoNT/A comprises a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain (He domain).
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: A
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 84 pg (preferably 84 pg to 666.7 pg) of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of a medicament for treating a disorder affecting an eyelid muscle of a subject, comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of a medicament for treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- SEQ ID NO: 2 comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991,
- One aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 90
- the invention provides a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or
- the invention provides a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- SEQ ID NO: 2 comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955,
- Another aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- the invention provides a method of treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- the invention provides a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hem
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- BoNT/A botulinum neurotoxin A
- a method of treating atypical hemifacial spasm wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032,
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- BoNT/A botulinum neurotoxin A
- the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032,
- the invention provides a method of treating atypical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032,
- the invention provides a method of treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081 , GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243,
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating atypical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032,
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating atypical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
- the unit dose of the modified BoNT/A is at least 84 pg of modified BoNT/A, wherein the total dose administered during the treatment is up to 2,000 pg of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081 , GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243,
- the unit dose may be at least 84.4 pg, 100 pg or 250 pg, wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: (i) substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; (ii) substitution of an acidic surface exposed amino
- the unit dose may be 84 pg to 666.7 pg of modified BoNT/A, wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991 , GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: (i) substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; (ii) substitution of an acidic
- An upper limit of the unit dose range may be 650, 600, 550, 500, 450, 400, 350, 333.3, 300, 250, 200, 166.7, 150, or 100 pg of modified BoNT/A.
- a lower limit of the unit dose range may be 100, 125, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, or 650 pg of modified BoNT/A.
- the unit dose may be 100 pg to 400 pg, 100 pg to 333.3 pg, 100 pg to 200 pg, or 100 pg to 166.7 pg-
- the unit dose may be greater than 300 pg or greater than 500 pg of modified BoNT/A, wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991 , GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: (i) substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; (ii) substitution of an acid
- a total dose administered when carrying out the treatment regimen of the present invention may be up to 2,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991 , GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081 , GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: (i) substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; (i
- the total amount of modified BoNT/A administered at a given treatment session may be up to 2,000 pg.
- the total dose may be up to 1 ,750, 1,500, 1 ,000, 750, 500, or 300 pg, preferably up to 1 ,500 pg.
- the total dose may be at least 252, 300, 350, 400, 500, 600, 700, 800, 900, 1 ,000, or 1 ,250 pg.
- the total dose may be 252 pg to 2,000 pg, preferably 300 pg to 1,500 pg.
- the total dose may be greater than 500 pg, or greater than 750 pg, or greater than 1 ,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991, GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081 , GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: (i) substitution of an acidic surface exposed amino acid residue with a basic
- the total dose may be greater than 500 pg and up to 2,000 pg of modified BoNT/A, wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 918, GLU 920, ASN 930, ASN 954, SER 955, GLN 991 , GLU 992, GLN 995, ASN 1006, ASN 1025, ASN 1026, ASN 1032, ASN 1043, ASN 1046, ASN 1052, ASP 1058, HIS 1064, ASN 1080, GLU 1081, GLU 1083, ASP 1086, ASN 1188, ASP 1213, GLY 1215, ASN 1216, GLN 1229, ASN 1242, ASN 1243, SER 1274, and THR 1277, wherein the modification is selected from: (i) substitution of an acidic surface exposed amino acid residue with a basic amino acid residue; (ii) substitution of an
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U of the modified BoNT/A, and
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the method comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 U of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, A
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject, the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 U of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue
- the invention provides a method of treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), the method comprising: administering a single unit dose of a modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U
- LD50
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of a medicament for treating a disorder affecting an eyelid muscle of a subject, comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of a medicament for treating a disorder affecting an eyelid muscle of a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- SEQ ID NO: 2 comprising: administering a single unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; administering a single unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and administering a single unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the single unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 915, ASN 9
- One aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 U of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 U of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U of the modified BoNT/A, and wherein the modified BoNT/
- the invention provides a method of treating blepharospasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 2
- LD50
- the invention provides a method of treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that correspond
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating blepharospasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- SEQ ID NO: 2 comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to a first eye of the subject; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to the first eye of the subject; and c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to the first eye of the subject, wherein the unit dose of the modified BoNT/A is at least 10 II of modified BoNT/A, wherein 1 Unit is an amount of the modified BoNT/A that corresponds to the calculated median lethal dose (LD50) in mice, wherein the total dose administered during the treatment is up to 237 U of the modified BoNT/A, and wherein the modified BoNT/A comprises a modification at one or more amino acid residue(s) selected from: ASN 886, ASN 905, GLN 9
- Another aspect provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in
- the invention provides a modified botulinum neurotoxin A (BoNT/A) for use in a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- the invention provides a method of treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- the invention provides a method of treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g. SEQ ID NO: 2), wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject, wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hem
- the invention provides the use of a modified botulinum neurotoxin A (BoNT/A) in the manufacture of medicament for treating typical hemifacial spasm in a subject for a longer duration than that treated by an unmodified BoNT/A (e.g.
- BoNT/A botulinum neurotoxin A
- the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, comprising: a) administering a unit dose of the modified BoNT/A to the lateral upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; b) administering a unit dose of the modified BoNT/A to the medial upper orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; c) administering a unit dose of the modified BoNT/A to the lateral lower orbicularis oculi muscle proximal to an eye affected by hemifacial spasm; and d) administering one or more unit dose of the modified BoNT/A to one or more further muscles affected by said hemifacial spasm in accordance with the following dosage regimen:
- BoNT/A botulinum neurotoxin A
- a method of treating atypical hemifacial spasm wherein the modified BoNT/A is administered by intramuscular injection at a plurality of sites of the face of the subject, the method comprising: a) administering a unit dose of the modified BoNT/A to an orbicularis oris muscle affected by hemifacial spasm (e.g.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pain & Pain Management (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202280064373.8A CN117979988A (zh) | 2021-09-23 | 2022-09-23 | 用于治疗影响受试者眼睑肌肉的疾病的修饰的BoNT/A |
CA3228712A CA3228712A1 (fr) | 2021-09-23 | 2022-09-23 | Bont/a modifiee destinee a etre utilisee dans le traitement d'un trouble affectant un muscle de la paupiere d'un sujet |
AU2022351260A AU2022351260A1 (en) | 2021-09-23 | 2022-09-23 | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB2113602.3 | 2021-09-23 | ||
GBGB2113602.3A GB202113602D0 (en) | 2021-09-23 | 2021-09-23 | Treatment of a disorder affecting an eyelid muscle of a subject |
GB2206360.6 | 2022-04-29 | ||
GBGB2206360.6A GB202206360D0 (en) | 2022-04-29 | 2022-04-29 | Treatment of a disorder affecting an eyelid muscle of a subject |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023047127A1 true WO2023047127A1 (fr) | 2023-03-30 |
Family
ID=83507580
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2022/052415 WO2023047127A1 (fr) | 2021-09-23 | 2022-09-23 | Bont/a modifiée destinée à être utilisée dans le traitement d'un trouble affectant un muscle de la paupière d'un sujet |
Country Status (3)
Country | Link |
---|---|
AU (1) | AU2022351260A1 (fr) |
CA (1) | CA3228712A1 (fr) |
WO (1) | WO2023047127A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023209327A1 (fr) * | 2022-04-29 | 2023-11-02 | Ipsen Biopharm Limited | Bont/a destinée à être utilisée dans le traitement d'une dystonie faciale |
WO2024069176A1 (fr) | 2022-09-28 | 2024-04-04 | Ipsen Biopharm Limited | Neurotoxines clostridiales comprenant un site de clivage de protéase exogène d'activation |
WO2024069175A1 (fr) | 2022-09-28 | 2024-04-04 | Ipsen Biopharm Limited | Neurotoxines clostridiennes comprenant un site de clivage de protéase endosomale d'activation |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006204A1 (fr) | 1990-09-28 | 1992-04-16 | Ixsys, Inc. | Banques de recepteurs heteromeres a expression en surface |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO2006027207A1 (fr) | 2004-09-06 | 2006-03-16 | Toxogen Gmbh | Proteine de transport pour l'introduction de composes chimiques dans des cellules nerveuses |
WO2006114308A2 (fr) | 2005-04-26 | 2006-11-02 | Toxogen Gmbh | Porteur destine a cibler des cellules nerveuses |
US20070166332A1 (en) | 2005-09-19 | 2007-07-19 | Allergan, Inc. | Clostridial Toxin Activatable Clostridial Toxins |
WO2010120766A1 (fr) | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Neurotoxine botulinique remaniée |
US20110318385A1 (en) | 2010-06-23 | 2011-12-29 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin c1 with selective substrate specificity |
WO2013180799A1 (fr) | 2012-05-30 | 2013-12-05 | President And Fellows Of Harvard College | Neurotoxine botulique génétiquement modifiée |
EP2677029A2 (fr) | 2011-05-19 | 2013-12-25 | Syntaxin Limited | Procédés de fabrication de polypeptides traités de manière protéolytique |
WO2014080206A1 (fr) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Procédés pour la fabrication de polypeptides traités de façon protéolytique |
WO2015004461A1 (fr) | 2013-07-09 | 2015-01-15 | Syntaxin Limited | Neurotoxines cationiques |
WO2015166242A1 (fr) | 2014-04-29 | 2015-11-05 | Ipsen Bioinnovation Limited | Fabrication de neurotoxines clostridium botulinum de recombinaison |
WO2016154534A1 (fr) | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Neurotoxine botulique ingéniérisée |
WO2017055274A1 (fr) | 2015-10-02 | 2017-04-06 | Ipsen Biopharm Limited | Procédé de purification de neurotoxine clostridienne |
WO2017191315A1 (fr) | 2016-05-05 | 2017-11-09 | Ipsen Biopharm Limited | Neurotoxines chimères |
-
2022
- 2022-09-23 WO PCT/GB2022/052415 patent/WO2023047127A1/fr active Application Filing
- 2022-09-23 CA CA3228712A patent/CA3228712A1/fr active Pending
- 2022-09-23 AU AU2022351260A patent/AU2022351260A1/en active Pending
Patent Citations (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1992006204A1 (fr) | 1990-09-28 | 1992-04-16 | Ixsys, Inc. | Banques de recepteurs heteromeres a expression en surface |
WO2006027207A1 (fr) | 2004-09-06 | 2006-03-16 | Toxogen Gmbh | Proteine de transport pour l'introduction de composes chimiques dans des cellules nerveuses |
WO2006114308A2 (fr) | 2005-04-26 | 2006-11-02 | Toxogen Gmbh | Porteur destine a cibler des cellules nerveuses |
US20070166332A1 (en) | 2005-09-19 | 2007-07-19 | Allergan, Inc. | Clostridial Toxin Activatable Clostridial Toxins |
WO2010120766A1 (fr) | 2009-04-14 | 2010-10-21 | Mcw Research Foundation, Inc. | Neurotoxine botulinique remaniée |
US20110318385A1 (en) | 2010-06-23 | 2011-12-29 | Wisconsin Alumni Research Foundation | Engineered botulinum neurotoxin c1 with selective substrate specificity |
EP2677029A2 (fr) | 2011-05-19 | 2013-12-25 | Syntaxin Limited | Procédés de fabrication de polypeptides traités de manière protéolytique |
EP2677029B1 (fr) | 2011-05-19 | 2017-05-10 | Ipsen Bioinnovation Limited | Procédés de fabrication de polypeptides traités de manière protéolytique |
EP2524963B1 (fr) | 2011-05-19 | 2018-10-31 | Ipsen Bioinnovation Limited | Procédés de fabrication de polypeptides traités de manière protéolytique |
WO2013180799A1 (fr) | 2012-05-30 | 2013-12-05 | President And Fellows Of Harvard College | Neurotoxine botulique génétiquement modifiée |
WO2014080206A1 (fr) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Procédés pour la fabrication de polypeptides traités de façon protéolytique |
WO2014079495A1 (fr) | 2012-11-21 | 2014-05-30 | Syntaxin Limited | Procédés pour réaliser des polypeptides traités de manière protéolytique |
US10087432B2 (en) | 2012-11-21 | 2018-10-02 | Ipsen Bioinnovation Limited | Methods for the manufacture of proteolytically processed polypeptides |
WO2015004461A1 (fr) | 2013-07-09 | 2015-01-15 | Syntaxin Limited | Neurotoxines cationiques |
WO2015166242A1 (fr) | 2014-04-29 | 2015-11-05 | Ipsen Bioinnovation Limited | Fabrication de neurotoxines clostridium botulinum de recombinaison |
WO2016154534A1 (fr) | 2015-03-26 | 2016-09-29 | President And Fellows Of Harvard College | Neurotoxine botulique ingéniérisée |
WO2017055274A1 (fr) | 2015-10-02 | 2017-04-06 | Ipsen Biopharm Limited | Procédé de purification de neurotoxine clostridienne |
WO2017191315A1 (fr) | 2016-05-05 | 2017-11-09 | Ipsen Biopharm Limited | Neurotoxines chimères |
Non-Patent Citations (41)
Title |
---|
ADLER SARAH ET AL: "The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for The Current Scientific and Legal Status of Alternative Methods to the LD50 Test for Botulinum Neurotoxin Potency Testing The Report and Recommendations of a ZEBET Expert Meeting", ALTERNATIVE TO LAB ANIMALS, vol. 18, no. 38, 1 January 2010 (2010-01-01), pages 315 - 330, XP055919796 * |
ALTSCHUL ET AL., BULL. MATH. BIO., vol. 48, 1986, pages 603 - 16 |
AOKI ET AL., EUR. J. NEUROL., vol. 6, 1999, pages S3 - S10 |
AOKI KR, TOXICON, vol. 39, 2001, pages 1815 - 1820 |
BOWIESAUER, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 6 |
BROIDE RSRUBINO JNICHOLSON GS ET AL.: "The rat Digit Abduction Score (DAS) assay: A physiological model for assessing botulinum neurotoxin-induced skeletal muscle paralysis", TOXICON, vol. 71, 2013, pages 18 - 24, XP028595208, DOI: 10.1016/j.toxicon.2013.05.004 |
C. E. LAWRENCE ET AL.: "Detecting Subtle Sequence Signals: A Gibbs Sampling Strategy for Multiple Alignment", SCIENCE, vol. 262, no. 5131, 1993, pages 208 - 214, XP001152872, DOI: 10.1126/science.8211139 |
CHADDOCK ET AL., PROTEIN EXPR. PURIF. EXPRESSION, 2002 |
CHOUDHURY SUPRIYO ET AL: "Botulinum Toxin: An Update on Pharmacology and Newer Products in Development", vol. 13, no. 1, 14 January 2021 (2021-01-14), pages 58, XP055916832, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7828686/pdf/toxins-13-00058.pdf> DOI: 10.3390/toxins13010058 * |
CHUNG ET AL., PROC. NATL. ACAD. SCI. USA, vol. 90, 1993, pages 10145 - 9 |
CHUNG ET AL., SCIENCE, vol. 259, 1993, pages 806 - 9 |
CUNNINGHAMWELLS, SCIENCE, vol. 244, 1989, pages 1081 - 5 |
DE VOS ET AL., SCIENCE, vol. 255, 1992, pages 306 - 12 |
DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145 |
ELLMAN ET AL., METHODS ENZYMOL, vol. 202, 1991, pages 301 |
ERIC DEPIEREUXERNEST FEYTMANS: "Match-Box: A Fundamentally New Algorithm for the Simultaneous Alignment of Several Protein Sequences", CABIOS, vol. 8, no. 5, 1992, pages 501 - 509 |
HALEMARHAM: "THE HARPER COLLINS DICTIONARY OF BIOLOGY", 1991 |
HALPERN J, J. BIOL. CHEM., vol. 268, no. 15, 1993, pages 11188 - 11192 |
HENIKOFFHENIKOFF, PROC. NATL. ACAD. SCI. USA, vol. 89, 1992, pages 10915 - 19 |
HERREROS J, BIOCHEM. J., vol. 347, 2000, pages 199 - 204 |
IVO VAN WALLE ET AL.: "Align-M - A New Algorithm for Multiple Alignment of Highly Divergent Sequences", BIOINFORMATICS, vol. 20, no. 9, 2004, pages 1428 - 1435 |
JULIE D. THOMPSON ET AL.: "CLUSTAL W: Improving the Sensitivity of Progressive Multiple Sequence Alignment Through Sequence Weighting", NUCLEIC ACIDS RESEARCH, vol. 22, no. 22, 1994, pages 4673 - 4680, XP002956304 |
KNAPP, AM. CRYST. ASSOC. ABSTRACT PAPERS, vol. 25, 1998, pages 90 |
KOIDE ET AL., BIOCHEM., vol. 33, 1994, pages 7470 - 6 |
LACEY DB, NAT. STRUCT. BIOL., vol. 5, 1998, pages 898 - 902 |
LOWMAN ET AL., BIOCHEM., vol. 30, 1991, pages 10832 - 7 |
MASUYER ET AL., J. STRUCT. BIOL. STRUCTURE, 2011 |
NER ET AL., DNA, vol. 7, 1988, pages 127 |
OSAMU GOTOH: "J. Mol. Biol.", vol. 264, 1996, article "Significant Improvement in Accuracy of Multiple Protein. Sequence Alignments by Iterative Refinement as Assessed by Reference to Structural Alignments", pages: 823 - 838 |
REIDHAAR-OLSONSAUER, SCIENCE, vol. 241, 1988, pages 53 - 7 |
ROBERTSON ET AL., J. AM. CHEM. SOC., vol. 113, 1991, pages 2722 |
RUMMEL A, MOL. MICROBIOL., vol. 51, no. 3, 2004, pages 631 - 643 |
RUMMEL A, PNAS, vol. 104, 2007, pages 359 - 364 |
SINGLETON ET AL.: "DICTIONARY OF MICROBIOLOGY AND MOLECULAR BIOLOGY", 1994, JOHN WILEY AND SONS |
SMITH ET AL., J. MOL. BIOL., vol. 224, 1992, pages 899 - 904 |
SWAMINATHANESWARAMOORTHY, NAT. STRUCT. BIOL., vol. 7, 2000, pages 1751 - 1759 |
TORII YGOTO YNAKAHIRA S ET AL.: "Comparison of Systemic Toxicity between Botulinum Toxin Subtypes A1 and A2 in Mice and Rats", BASIC CLIN. PHARMACOL. TOXICOL., vol. 116, 2015, pages 524 - 528 |
TURCATTI ET AL., J. BIOL. CHEM., vol. 271, 1996, pages 19991 - 8 |
UMLAND TC, NAT. STRUCT. BIOL., vol. 4, 1997, pages 788 - 792 |
WLODAVER ET AL., FEBS LETT, vol. 309, 1992, pages 59 - 64 |
WYNNRICHARDS, PROTEIN SCI, vol. 2, 1993, pages 395 - 403 |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023209327A1 (fr) * | 2022-04-29 | 2023-11-02 | Ipsen Biopharm Limited | Bont/a destinée à être utilisée dans le traitement d'une dystonie faciale |
WO2024069176A1 (fr) | 2022-09-28 | 2024-04-04 | Ipsen Biopharm Limited | Neurotoxines clostridiales comprenant un site de clivage de protéase exogène d'activation |
WO2024069175A1 (fr) | 2022-09-28 | 2024-04-04 | Ipsen Biopharm Limited | Neurotoxines clostridiennes comprenant un site de clivage de protéase endosomale d'activation |
Also Published As
Publication number | Publication date |
---|---|
CA3228712A1 (fr) | 2023-03-30 |
AU2022351260A1 (en) | 2024-02-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017260389B2 (en) | Chimeric neurotoxins | |
US20230346674A1 (en) | Treatment of Upper Facial Lines | |
JP5764072B2 (ja) | 改変非細胞毒性プロテアーゼ | |
AU2022351260A1 (en) | Modified bont/a for use in the treatment of a disorder affecting an eyelid muscle of a subject | |
US20230248811A1 (en) | Treatment of Limb Spasticity | |
AU2022348206A1 (en) | Modified bont/a for use in the treatment of cervical dystonia | |
US20230038233A1 (en) | Treatment of neurological disorders | |
JP2024510786A (ja) | 外来性の活性化ループを含むクロストリジウム神経毒素 | |
AU2021438810A1 (en) | Catalytically inactive clostridial neurotoxins for the treatment of pain & inflammatory disorders | |
KR20240067100A (ko) | 대상체의 안검 근육에 이환된 장애의 치료에 사용하기 위한 변형된 bont/a | |
WO2023209327A1 (fr) | Bont/a destinée à être utilisée dans le traitement d'une dystonie faciale | |
WO2023209403A1 (fr) | Traitement des rides supérieures du visage | |
KR20240067070A (ko) | 경부 이상긴장증의 치료에 사용하기 위한 변형된 bont/a | |
CN117979988A (zh) | 用于治疗影响受试者眼睑肌肉的疾病的修饰的BoNT/A | |
WO2023209326A1 (fr) | Traitement de la dystonie cervicale | |
WO2023209385A1 (fr) | Traitement de la spasticité des membres | |
US20240082368A1 (en) | Treatment of Brain Damage | |
AU2022390672A1 (en) | Treatment of visceral pain | |
WO2023089338A1 (fr) | Traitement de la douleur viscérale |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22782758 Country of ref document: EP Kind code of ref document: A1 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 3228712 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: AU2022351260 Country of ref document: AU |
|
ENP | Entry into the national phase |
Ref document number: 2022351260 Country of ref document: AU Date of ref document: 20220923 Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112024003828 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 202280064373.8 Country of ref document: CN |
|
ENP | Entry into the national phase |
Ref document number: 20247012920 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2022782758 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2022782758 Country of ref document: EP Effective date: 20240423 |